• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PI3K/Akt/mTOR 信号通路在胃癌中的作用。

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.

机构信息

Department of Surgical Oncology, Osaka City University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan.

出版信息

Cancers (Basel). 2014 Jul 7;6(3):1441-63. doi: 10.3390/cancers6031441.

DOI:10.3390/cancers6031441
PMID:25003395
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4190549/
Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the key signaling pathways induced by various receptor-tyrosine kinases. Accumulating evidence shows that this pathway is an important promoter of cell growth, metabolism, survival, metastasis, and resistance to chemotherapy. Genetic alterations in the PI3K/Akt/mTOR pathway in gastric carcinoma have often been demonstrated. Many kinds of molecular targeting therapies are currently undergoing clinical testing in patients with solid tumors. However, with the exception of the ErbB2-targeting antibody, targeting agents, including PI3K/Akt/mTOR inhibitors, have not been approved for treatment of patients with gastric carcinoma. This review summarizes the current knowledge on PI3K/Akt/mTOR signaling in the pathogenesis of gastric carcinoma and the possible therapeutic targets for gastric carcinoma. Improved knowledge of the PI3K/Akt/mTOR pathway in gastric carcinoma will be useful in understanding the mechanisms of tumor development and for identifying ideal targets of anticancer therapy for gastric carcinoma.

摘要

磷脂酰肌醇 3-激酶（PI3K）/Akt/雷帕霉素靶蛋白（mTOR）通路是多种受体酪氨酸激酶诱导的关键信号通路之一。越来越多的证据表明，该通路是细胞生长、代谢、存活、转移和化疗耐药的重要促进因素。在胃癌中已经经常证明 PI3K/Akt/mTOR 通路的遗传改变。目前正在对实体瘤患者进行多种针对分子靶点的治疗的临床试验。然而，除了针对 ErbB2 的抗体靶向药物外，包括 PI3K/Akt/mTOR 抑制剂在内的靶向药物尚未被批准用于治疗胃癌患者。这篇综述总结了目前关于 PI3K/Akt/mTOR 信号通路在胃癌发病机制中的作用及其作为胃癌治疗靶点的可能性。对胃癌中 PI3K/Akt/mTOR 通路的深入了解将有助于理解肿瘤发展的机制，并确定用于胃癌的抗癌治疗的理想靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/4702860d50b0/cancers-06-01441-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/5e76fcbe6838/cancers-06-01441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/b2bc4b3c5109/cancers-06-01441-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/4702860d50b0/cancers-06-01441-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/5e76fcbe6838/cancers-06-01441-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/b2bc4b3c5109/cancers-06-01441-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa66/4190549/4702860d50b0/cancers-06-01441-g003.jpg

相似文献

1
The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.PI3K/Akt/mTOR 信号通路在胃癌中的作用。
Cancers (Basel). 2014 Jul 7;6(3):1441-63. doi: 10.3390/cancers6031441.
2
Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.针对磷脂酰肌醇 3-激酶 (PI3K)/AKT/哺乳动物雷帕霉素靶蛋白 (mTOR) 通路：治疗鳞状细胞肺癌的新兴策略。
Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Epub 2014 Jul 3.
3
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.克服癌症治疗获得性耐药：聚焦 PI3K/AKT/mTOR 通路。
Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Epub 2013 Feb 3.
4
Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.抑制趋化因子（CXC 基序）配体 12/趋化因子（CXC 基序）受体 4 轴（CXCL12/CXCR4）-介导的人胃癌细胞中的哺乳动物雷帕霉素靶蛋白（mTOR）途径细胞迁移。
J Biol Chem. 2012 Apr 6;287(15):12132-41. doi: 10.1074/jbc.M111.302299. Epub 2012 Feb 15.
5
Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.针对雌激素受体阳性乳腺癌中的 PI3K/AKT/mTOR 通路。
Cancer Treat Rev. 2014 Aug;40(7):862-71. doi: 10.1016/j.ctrv.2014.03.004. Epub 2014 Mar 26.
6
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.PI3K/AKT/mTOR 通路中癌症治疗的分子靶点。
Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9.
7
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention.PI3K/Akt/mTOR信号通路抑制剂在前列腺癌化学预防和干预中的作用
Pharmaceutics. 2021 Aug 3;13(8):1195. doi: 10.3390/pharmaceutics13081195.
8
PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy.PI3K/Akt/mTOR信号通路：在食管鳞状细胞癌中的作用、调控机制及靶向治疗机会
Front Oncol. 2022 Mar 22;12:852383. doi: 10.3389/fonc.2022.852383. eCollection 2022.
9
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.HER2 阳性胃癌的基因组分析：PI3K/Akt/mTOR 通路作为曲妥珠单抗治疗 HER2 阳性晚期胃癌结局的预测因子。
Oncologist. 2018 Sep;23(9):1092-1102. doi: 10.1634/theoncologist.2017-0379. Epub 2018 Apr 26.
10
Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer.PI3K 和 mTOR 抑制剂作为乳腺癌抗癌药物的现状和未来展望。
Curr Cancer Drug Targets. 2013 Feb;13(2):175-87. doi: 10.2174/1568009611313020007.

引用本文的文献

1
Claudin18.2 as a Promising Therapeutic Target in Gastric Cancer.Claudin18.2作为胃癌中一个有前景的治疗靶点。
Cells. 2025 Aug 19;14(16):1285. doi: 10.3390/cells14161285.
2
Ferroptosis and gastric cancer: from molecular mechanisms to clinical implications.铁死亡与胃癌：从分子机制到临床意义
Front Immunol. 2025 Aug 11;16:1581928. doi: 10.3389/fimmu.2025.1581928. eCollection 2025.
3
Circular RNA vaccines: Pioneering the next-gen cancer immunotherapy.环状RNA疫苗：开创下一代癌症免疫疗法。

本文引用的文献

1
PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.PAK4通过PI3K/Akt和MEK/ERK依赖的途径赋予胃癌细胞顺铂耐药性。
Biosci Rep. 2014 Apr 1;34(2). doi: 10.1042/BSR20130102.
2
Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression.PTEN（磷酸酶和张力蛋白同源物）在胃癌发生和发展中的作用。
Asian Pac J Cancer Prev. 2014;15(1):17-24. doi: 10.7314/apjcp.2014.15.1.17.
3
PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression.
Cancer Pathog Ther. 2024 Dec 4;3(4):309-321. doi: 10.1016/j.cpt.2024.11.003. eCollection 2025 Jul.
4
Coumarin derivatives as anticancer agents targeting PI3K-AKT-mTOR pathway: a comprehensive literature review.香豆素衍生物作为靶向PI3K-AKT-mTOR通路的抗癌剂：一项全面的文献综述。
Med Oncol. 2025 Jun 30;42(8):301. doi: 10.1007/s12032-025-02844-9.
5
XGB-BIF: An XGBoost-Driven Biomarker Identification Framework for Detecting Cancer Using Human Genomic Data.XGB-BIF：一种用于利用人类基因组数据检测癌症的基于XGBoost的生物标志物识别框架。
Int J Mol Sci. 2025 Jun 11;26(12):5590. doi: 10.3390/ijms26125590.
6
Dihydrotestosterone-androgen receptor signaling suppresses EBV-positive gastric cancer through DNA demethylation-mediated viral reactivation.双氢睾酮 - 雄激素受体信号通路通过DNA去甲基化介导的病毒再激活抑制EBV阳性胃癌。
Gastric Cancer. 2025 Jun 12. doi: 10.1007/s10120-025-01626-6.
7
Pro-Apoptotic Effects of Anandamide in Human Gastric Cancer Cells Are Mediated by AKT and ERK Signaling Pathways.花生四烯酸乙醇胺对人胃癌细胞的促凋亡作用由AKT和ERK信号通路介导。
Int J Mol Sci. 2025 Feb 26;26(5):2033. doi: 10.3390/ijms26052033.
8
Potential mechanism of traditional Chinese medicine intervention in gastric cancer: targeted regulation of autophagy.中医药干预胃癌的潜在机制：自噬的靶向调控
Front Pharmacol. 2025 Feb 18;16:1548672. doi: 10.3389/fphar.2025.1548672. eCollection 2025.
9
PLASMA: Partial LeAst Squares for Multiomics Analysis.血浆：用于多组学分析的偏最小二乘法
Cancers (Basel). 2025 Jan 17;17(2):287. doi: 10.3390/cancers17020287.
10
Consensus molecular subtyping of colorectal carcinoma brain metastases reveals a metabolic signature associated with poor patient survival.结直肠癌脑转移的共识分子亚型分析揭示了一种与患者生存不良相关的代谢特征。
Mol Oncol. 2025 Mar;19(3):614-634. doi: 10.1002/1878-0261.13748. Epub 2025 Jan 17.
PTEN通过下调FAK表达抑制胃癌的侵袭和转移。
Cell Signal. 2014 May;26(5):1011-20. doi: 10.1016/j.cellsig.2014.01.025. Epub 2014 Jan 29.
4
SN50 enhances the effects of LY294002 on cell death induction in gastric cancer cell line SGC7901.SN50 增强了 LY294002 对胃癌细胞系 SGC7901 细胞死亡诱导的作用。
Arch Med Sci. 2013 Dec 30;9(6):990-8. doi: 10.5114/aoms.2013.39790. Epub 2013 Dec 26.
5
Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells.三氧化二砷使Akt失活通过线粒体介导的凋亡信号通路诱导SGC - 7901人胃癌细胞死亡。
Oncol Rep. 2014 Apr;31(4):1645-52. doi: 10.3892/or.2014.2994. Epub 2014 Jan 24.
6
HER2 expression and PI3K-Akt pathway alterations in gastric cancer.胃癌中 HER2 表达和 PI3K-Akt 通路改变。
Digestion. 2014;89(1):12-7. doi: 10.1159/000356201. Epub 2014 Jan 20.
7
The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway.RAD001 与 MK-2206 联合对 PTEN 突变型胃癌细胞具有协同细胞毒性作用：涉及 MAPK 依赖性自噬，但不涉及凋亡细胞死亡途径。
PLoS One. 2014 Jan 9;9(1):e85116. doi: 10.1371/journal.pone.0085116. eCollection 2014.
8
miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a.miR-338-3p 通过靶向 P-REX2a 抑制 PTEN-AKT 轴抑制胃癌进展。
Mol Cancer Res. 2014 Mar;12(3):313-21. doi: 10.1158/1541-7786.MCR-13-0507. Epub 2013 Dec 27.
9
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.一项评估变构AKT抑制剂（MK-2206）与曲妥珠单抗联合用于HER2阳性实体瘤患者的1期研究。
Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577.
10
The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway.叉头框转录因子 FOXO1 通过激活磷脂酰肌醇 3-激酶/ Akt 通路介导胃癌细胞对顺铂的耐药性。
Gastric Cancer. 2014;17(3):423-30. doi: 10.1007/s10120-013-0314-2. Epub 2013 Nov 8.